Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) – Cantor Fitzgerald investment analysts released their FY2021 EPS estimates for Biohaven Pharmaceutical in a research note to investors on Tuesday, Jan.4. Cantor Fitzgerald analyst C. Duncan predicts the company will earn ($ 12.10) per share for the year. Cantor Fitzgerald has an “overweight” rating and a target price of $ 177.00 on the stock. Cantor Fitzgerald also released Biohaven Pharmaceutical’s earnings estimates for fiscal 2022 at ($ 7.74) per share.
Other research analysts have also published reports on the stock. The UBS group raised its target price on shares of Biohaven Pharmaceutical from $ 150.00 to $ 160.00 in a research note on Tuesday. Morgan Stanley increased its target price on Biohaven Pharmaceutical shares from $ 107.00 to $ 145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 19. The Goldman Sachs group raised its target price on Biohaven Pharmaceutical shares from $ 151.00 to $ 170.00 and assigned the stock a “buy” rating in a research note on Wednesday, October 6. Mizuho raised his price target for Biohaven Pharmaceutical shares from $ 135 to $ 144.00 and assigned the company a “buy” rating in a research note on Thursday, November 18. Finally, SVB Leerink reaffirmed a “buy” note on shares of Biohaven Pharmaceutical in a research note on Thursday, October 7. Three research analysts rated the stock with a conservation rating and nine gave the company a buy rating. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $ 147.27.
NYSE BHVN shares opened at $ 123.86 on Thursday. The company has a market cap of $ 8.11 billion, a PE ratio of -9.05 and a beta of 1.03. Biohaven Pharmaceutical has a 12 month low of $ 62.57 and a 12 month high of $ 151.51. The company’s fifty-day simple moving average is $ 123.36 and its 200-day simple moving average is $ 124.39. Biohaven Pharmaceutical (NYSE: BHVN) last released its quarterly earnings data on Monday, November 8. The company reported ($ 2.63) EPS for the quarter, missing Zacks’ consensus estimate of ($ 2.40) of ($ 0.23). The company posted revenue of $ 135.74 million for the quarter, compared to the consensus estimate of $ 128.40 million. In the same quarter of the previous year, the company posted ($ 3.27) earnings per share. The company’s revenue grew 668.5% year-over-year.
In addition, Director Declan Doogan sold 37,740 shares of Biohaven Pharmaceutical in a transaction dated Tuesday, November 16. The shares were sold for an average price of $ 116.65, for a total value of $ 4,402,371.00. The transaction was disclosed in a file with the Securities & Exchange Commission, which is available at this link. In addition, CAO George C. Clark sold 1,915 shares of Biohaven Pharmaceutical in a transaction dated Monday, December 20. The stock was sold for an average price of $ 123.84, for a total trade of $ 237,153.60. Disclosure of this sale can be found here. Insiders sold 133,099 shares of the company valued at $ 14,807,430 in the past 90 days. 15.20% of the shares are currently held by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of BHVN. Marshall Wace LLP purchased a new position in shares of Biohaven Pharmaceutical during the first quarter valued at approximately $ 365,000. Advisor Group Holdings Inc. increased its stake in Biohaven Pharmaceutical shares by 6.4% during the second quarter. Advisor Group Holdings Inc. now owns 2,275 shares of the company valued at $ 221,000 after acquiring 137 additional shares in the last quarter. Russell Investments Group Ltd. increased its stake in Biohaven Pharmaceutical shares by 87.2% during the second quarter. Russell Investments Group Ltd. now owns 53,892 shares of the company valued at $ 5,231,000 after acquiring 25,103 additional shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Biohaven Pharmaceutical by 8.5% during the second quarter. Envestnet Asset Management Inc. now owns 3,763 shares of the company valued at $ 365,000 after acquiring 294 additional shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in Biohaven Pharmaceutical shares by 17.8% during the second quarter. Teacher Retirement System of Texas now owns 6,594 shares of the company valued at $ 640,000 after acquiring an additional 997 shares during the last quarter. Hedge funds and other institutional investors hold 91.05% of the company’s shares.
Profile of the pharmaceutical company Biohaven
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It focuses on a pipeline of product candidates that represent mechanistic platforms, peptide receptor antagonists linked to the calcitonin gene, and glutamate modulators.
Featured Article: How To Use The MarketBeat Retirement Calculator
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Biohaven Pharmaceutical was not on the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here